Are serum neopterin concentrations superior to other parameters in the differential diagnosis and prognostic assessment of Graves' disease?

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 2, 1996, Pages 123-129

  Schomburg, A ^a   Grunwald F ^a   Schultes, B ^a   Hotze, A ^a   Bender, H ^a   Biersack, H J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Graves' disease; Hyperthyroidism; Neopterin; Plummer's disease

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; IODINE 131; NEOPTERIN; PROPYLTHIOURACIL; THIAMAZOLE; THYROXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY;

EID: 0029874171     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211433     Document Type: Article

References (32)

1. Backer W, Börner W: Therapeutische Konsequenzen aus der Pathogenese der Hyperthyreose. Medwelt 37: 649-653, 1986.
2. Bottazzo GF, Doniach D: Autoimmune thyroid disease. Annu Rev Med 37: 353-359, 1986.
3. Derwahl M, Schatz H, Bolle B, Pohl A, Meyer K: Measurement of stimulating TSH receptor antibodies in sera of patients with Graves' disease by recombinant TSH receptor bioassay. Exp Clin Endocrinol 100: 75-79, 1992.
4. Hagihara M, Nagatsu T, Ohhashi M, Takayuki M: Concentrations of neopterin and biopterin in rheumatoid arthritis. Clin Chem 36: 705-706, 1990.
5. Hönlinger M, Fuchs D, Hausen A, Reibnegger D, Schönitzer D, Werner ER, Reissigl H, Dierich MP: Serum-Neopterinbestimmung zur zusätzlichen Sicherung der Bluttransfusion. DMW 114: 172-176, 1989.
6. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160: 310-316, 1984.
7. Ikenoue H, Okamura K, Sato K, Kuroda T, Yoshinari M, Tokuyama T, Nakagawa M, Fujishima M: Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices. Acta Endocrinol (Copenh) 125: 643-650, 1991.
8. Jackson RA, Haynes BF, Burch WM, Shimizu K, Bowring MA, Eisenbarth GS: Ia positive T cells in new onset Graves' disease. J Clin Endocrinol Metab 59: 187-190, 1984.
9. Kaise K, Kaise N, Yoshida K, Fukazawa H, Mori K, Yamamoto M, Sakurada T, Saito S, Yoshinaga K: Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine therapy for hyperthyroid Graves' disease. Endocrinol Jpn 38: 429-433, 1991.
10. Klein I, Trzepacz PT, Roberts M, Levey GS: Symptom rating scale for assessing hyperthyroidism. Arch Intern Med 148: 387-390, 1988.
11. Lissoni P, Brivio F, Fumagalli L, Galimberti C, Cataldo M, Marsili MT, Brivio O, Barni S, Tancini G, Angelini A: A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors. J Biol Regul Homeost Agents 8: 32-35, 1994.
12. Maerker-Alzer G, Diemer O, Strümper R, Rohe M: Neopterin production in inflamed knee joints. Rheumatol Int 6: 151-154, 1986.
13. McGregor AM, Weetman AP, Rennie DP, Hall R: Characterisation of the influence of methimazole on the thyroidal autoimmune response. In: Doniach D, Schleusener H, Weinheimer B (eds.). Current topics in thyoid autoimmunity. Thieme, Stuttgart New York 146-150, 1984.
14. Melichar B, Zeimet A, Artner-Dworzak E, Schröcksnadel H, Marth C, Wachter H, Fuchs D: Association between increased urinary zinc and neopterin concentrations in gynaecological cancer. Tumordiagn u Ther 14: 110-112, 1993.
15. Moser E, Pickardt CR, Mann K: Ergebnisse der Radiojodbehandlung von Patienten mit immunogener und nichtimmunogener Hyperthyreose bei Anwendung unterschiedlicher Herddosen. Nucl Med 27: 98-104, 1988.
16. Niederweiser D, Fuchs D, Hausen A, Judmaier G, Reibnegger G, Wachter H, Huber C: Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitits. Immunobiol 170: 320-326, 1985.
17. Okamoto T, Fujimoto Y, Obra T, Ito Y, Aiba M: Retrospective analysis of prognostic factors affecting the thyroid functional status after subtotal thyroidectomy for Graves' disease. World J Surg 16: 690-696, 1992.
18. Peters K, Bruchhausen B, Leusch HG, Forst R: Selection of cancellous bone donors for the bone bank. DMW 116: 1897-1902, 1991.
19. Pohl M, Emrich D: Immunogenic and non-immunogenic hyperthyroidism - a comparison. Nucl.-Med. 32: 200-205, 1993.
20. Prior C, Bollbach R, Fuchs D, Hausen A, Judmaier G, Niederwieser D, Reibnegger G, Rothauwe HW, Werner ER, Wachter H: Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chem Acta 155: 11-22, 1986.
21. Reibnegger G, Egg D, Fuchs D, Günther R, Hausen A, Werner ER, Wachter H: Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum 29: 1063-1070, 1986.
22. Reinwein D, Benker G, König MP: The different types of hyperthyroidism in Europe. Results of a prospective survey of 924 patients, J Endocr Invest 11: 193-200, 1988.
23. Schicha H: Differential diagnosis of hyperthyroidism. Exp Clin Endocr 97: 217-223, 1991.
24. Schleusener H, Schwander J, Fischer C: Prospective multicentre study on the prediction of relapse after anti-thyroid drug treatment in patients with Graves' disease. Acta Endocrinol 6: 689-701, 1989.
25. Schödon G, Troppmair S, Adolf C, Huber A, Niederwieser A: Interferon-gamma enhances biosynthesis of pteridins in peripheral blood mononuclear cells by induction of GTP-cyclohydrolase activity. J Interferon Res 6: 697-703, 1986.
26. Schreiber L: Neopterin in Graves' disease. Cas Lek Cesk 128: 883-884, 1989.
27. Solomon B, Glinoer D, Lagasse R, Wartofsky L: Current trends in the management of Graves' disease. J Clin Endocrinol Metab 70: 1518-1523, 1990.
28. Studer H, Huber G, Derwahl M, Frey P: Die Umwandlung von Basedowstrumen in Knotenkröpfe: Ein Grund des Hyperthyreoserezidivs. Schweiz Med Wschr 119: 203-208, 1989.
29. Vitti P, Rago T, Mancusi F, Pallini S, Tonacchera M, Santini F, Chiovato L, Marcocci C, Pinchera A: Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease. Acta Endocrinol 126: 128-131, 1992.
30. Wagner R, Hayatghebi S, Rosenkranz M, Reinwein D: Increased serum neopterin levels in patients with Graves' disease. Exp Clin Endocrinol 101: 249-254, 1993.
31. Weetman AP, Ratanachaiyavong S, Middleton GW: Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 228: 409-419, 1985.
32. Wilson R, McKillop D, Pearson DWM, Cuthbert GF, Thomson JA: Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. J Nucl Med 26: 1024-1028, 1985.